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Cancer immunotherapy has been the focus of intense research since the late 19th century when Coley observed that bacterial
components can contribute to cancer regression by eliciting an antitumor immune response. Successful activation and maturation
of tumor-speciﬁc immune cells is now known to be mediated by bacterial endotoxin, which activates Toll-like receptor 4 (TLR4).
TLR4isexpressedonavarietyofimmuneaswellastumorcells,butitsactivationcanhaveopposingeﬀects.WhileTLR4activation
can promote antitumor immunity, it can also result in increased tumor growth and immunosuppression. Nevertheless, TLR4
engagement by endotoxin as well as by endogenous ligands represents notable contribution to the outcome of diﬀerent cancer
treatments, such as radiation or chemotherapy. Further research of the role and mechanisms of TLR4 activation in cancer may
provide novel antitumor vaccine adjuvants as well as TLR4 inhibitors that could prevent inﬂammation-induced carcinogenesis.
1.Introduction
Immune system plays a crucial role not only in defense
against microbial infection but also in control and surveil-
lance of malignant neoplasms. Immune cells scan tissues
with the objective to remove newlyformed malignant cells
before they turn into fully formed tumors. Malignant cells
developed intricate mechanisms that enable them to inhibit
immune cells through secretion of speciﬁc cytokines that
create an immunosuppressive environment [1]. Tumors can
even directly kill tumor-inﬁltrating lymphocytes, which are
CD95 sensitive, by expressing the CD95L (Fas ligand) [2].
Innateimmunityistheﬁrstlineofdefenseagainstmicro-
bial infection. Innate immune cells recognize the intruding
pathogen and trigger appropriate immune response with
the help of Toll-like receptors (TLRs), arguably the most
important vertebrate innate immune receptors. TLRs recog-
nizediﬀerentmoleculesofmicrobialorigin,calledpathogen-
associated molecular patterns. TLRs are located on the cell
surface (TLR1, 2, 4, 5, 6) or in the endosomal compartments
(TLR3, 7, 8, 9), where they safeguard the organism against
infection. After recognition of their respective ligands, TLRs
dimerize and trigger a cytoplasmic signaling pathway that
leadstoactivation ofseveralnuclearfactors(e.g.,NFκB, IRF)
responsible for transcription of immune genes [3].
Toll-like receptor signaling in immune cells is critical
for regulation of innate and adaptive immune responses,
such as DC maturation and antigen presentation as well
as CD8+ T-cell cytotoxicity, all of which are important
factors in antitumor immunity [4]. On the other hand,
TLR stimulation can also result in enhanced regulatory T-
cell proliferation and suppressor function favoring tumor
development[5–7].TLRexpressionisnotlimitedtoimmune
cells, and indeed many tumor cells have been found to
express TLRs, signaling through which can promote tumor
growth and immune evasion [8, 9]. On the other hand,
TLR signaling in tumor cells was also shown to reduce
the proliferative capacity of tumor cells [10]. We will focus2 Clinical and Developmental Immunology
on reports concerning TLR4 signaling and its involvement
in cancer development and progression as well as the
therapeutic beneﬁt that could come from TLR4 stimulation.
2. Toll-Like Receptor 4 inHealth andDisease
TLRs are homologues of Toll, a receptor found in insects,
that is involved in establishing dorsoventral polarity during
embryogenesis as well as in immune response against fungal
infections [11, 12]. The ﬁrst discovered human Toll homo-
logue was TLR4. It recognizes endotoxin (i.e., lipopolysac-
charide), an outer membrane component of Gram-negative
bacteria,thatiscomposedofaconservedamphipathiclipidA
component and of variable polysaccharides. The mechanism
of TLR4 activation is quite complex and (unlike other TLRs)
involves several auxiliary proteins (LBP, CD14) as well as
a coreceptor (MD-2) [3]( Figure 1). It is in fact MD-2
and not TLR4 that directly recognizes and binds endotoxin
[13, 14]. MD-2 is a soluble protein with a large hydrophobic
pocket that represents the binding site for the acyl chains
of lipid A. Lipid A is usually composed of 6 acyl chains,
but only 5 of them bind into the hydrophobic pocket of
MD-2. The 6th acyl chain protrudes out of the pocket and
interacts with hydrophobic residues on TLR4. These inter-
actions are crucial for MD-2/TLR4 heterodimerization and
thereforeprerequisitefortheactivationoftheTLR4signaling
cascade [15, 16]. The endotoxin/MD-2/TLR4 heterodimer
can, unlike other TLR signaling complexes, recruit two
distinct intracellular adaptor proteins (i.e., MyD88/TIRAP
and TRIF/TRAM) and can therefore activate two parallel
signaling pathways and trigger the transcription of both
proinﬂammatory cytokines as well as type I interferons [3].
Immune eﬀects of TLR4 activation are indeed extensive; LPS
alonecanactivateover1000genes[17]. It is therefore not too
surprising that TLR4 activation aﬀects not only the immune
response against invading Gram-negative bacteria but is also
involved in chronic inﬂammation, autoimmune diseases,
and malignancies. TLR4 signaling in cancer is considered
a double-edged sword. If TLR4 is activated on immune
cells, it can enhance anti-tumor immunity. On the other
hand, chronic inﬂammation is a major risk factor in cancer
development [18].
3. TLR4 Expressionin Cancer Cells
Progress in cancer research over the past decade has been
immense, and the original fundamental characteristics of
cancer (sustained proliferative signaling, evasion of growth
suppressors, resistance to cell death, replicative immortality,
induction of angiogenesis, invasion, and metastasis) [19]
haverecentlybeenrevisitedandupdated.Evasionofimmune
destruction rises as a new emerging hallmark of cancer
[20]. Tumors utilize multiple mechanisms that help them
turn the immune balance in their favor. They can secrete
immunosuppressive cytokines (TGFβ, IL-10, etc.), express
antiapoptotic molecules, or downregulate tumor antigens
and MHC1 expression [1]. TLRs are expressed by a vari-
ety of tumor cell lines, both in mouse and in human
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Figure 1: TLR4/MD-2 receptor complex recognizes and binds
endotoxin. (a) MD-2 (shown in blue ribbons) is a soluble protein
with a large hydrophobic pocket that directly binds bacterial endo-
toxin (red). One of the acyl chains of endotoxin (yellow) remains
outside the hydrophobic pocket and mediates crucial interactions
with TLR4 that bind the TLR4/MD-2 heterodimer together. Left:
direct view of the MD-2 hydrophobic pocket. Right: side view
showing the protruding endotoxin acyl chain. (b) The TLR4/MD-
2/endotoxin heterodimer. Only the extracellular domains of TLR4
whose crystal structures were determined are shown [16].
Table 1: Murine tumor cell lines that express TLR4.
Tumor type Murine tumor cell line References
Breast cancer 4T1 [8]
Colon cancer MC26 [8]
Glioma GL261 [21]
Lung cancer LLC1 [8]
Melanoma B16 [8]
Prostate cancer RM1 [8]
(Tables 1 and 2). Many of them are not limited to a single
TLR but rather utilize an assortment of diﬀerent TLRs
(similarly to immune cells).
Expression of TLR4 was conﬁrmed by RT-PCR and
FACS analysis on a large number of murine tumor cells,
such as colon, breast, prostate, lung, and melanoma cancer
cells. TLR4 signaling was shown to be unimpaired and
could induce the synthesis of soluble immune mediators
that could help the tumor to withstand the immune attack
[8]. MC26 cells, for example, were shown to express func-
tional TLR4 that (when activated by endotoxin) triggeredClinical and Developmental Immunology 3
Table 2: Human tumor cell lines that express TLR4.
Tumor type Human tumor cell line References
Bladder cancer T24 [22]
Breast cancer MDA-MB-231 [23]
Colon cancer SW480, HT29, KM20 [24, 25]
Laryngeal and oral cancer PCI-1, PCI-30 [26]
Melanoma SkMEL-28, BN1, 9923M, ME5, ME16, ME17 [27, 28]
Neuroblastoma NB-1 [29]
Ovarian cancer SKOV3, AD10, A2780, CP70 [9, 30, 31]
activation of NF-κB, ERK, and JNK kinases as well as the
synthesis of iNOS, IL-6, and IL-12p70 [8]. iNOS and IL-
6 have immunosuppressive eﬀects [32–34], but IL-12p70 is
generally not considered favorable for tumor development
since it activates NK cells, induces T-cell proliferation, and
promotes speciﬁc allogenic CTL reactions [35]. Some papers
indicate that IL-12p70 can also have suppressive eﬀects on
allogenic or tumor-speciﬁc CTL generation [36, 37], but
since evidence undisputedly demonstrates anti-tumor eﬀects
for IL-12 its production by tumor cells is possibly just a
side product of TLR4 activation and subsequent NF-κB
activation.
Supernatants from endotoxin-stimulated tumor cells
were shown to inhibit T-cell proliferation and NK-cell
cytotoxicity.Furthermore,blockadeoftumorTLR4signaling
with anti-TLR4 siRNA or with inhibitory TLR4 peptide
treatment prolongs the survival of MC26-bearing mice [8].
Functional TLR4 signaling was also demonstrated on
human tumor cells. On colon carcinoma cells TLR4 signal-
ing,inadditiontoproductionofimmunosuppressivefactors,
also improved tumor cell apoptosis resistance [24]. More-
over, endotoxin stimulation of human prostate epithelial
cancer cells elicited production of immunosuppressive and
proangiogenic factors (TGF-beta and VEGF, resp.) [38].
TLR4isexpressednotonlyonmalignantcellsbutalsoon
normal tissues and benign tumors [30, 31]. Much remains
to be studied concerning the function of TLR4 on normal
nonimmune tissues in correlation with cancer development.
But we must not forget to examine the expression of other
contributing proteins in the TLR4 signaling cascade, for
example, the adapter protein MyD88 (myeloid diﬀerenti-
ation 88) that is essential for pro-inﬂammatory signaling.
Although TLR4 expression was shown in normal ovarian
epithelium, MyD88 was not expressed, therefore rendering
TLR4 signaling via the proinﬂammatory MyD88-dependent
pathway nonfunctional [9, 30]. Similar observation was
made in a variety of colorectal carcinoma cell lines where
tumor cells expressed TLR4 but failed to coexpress CD14,
an important auxiliary protein in the endotoxin receptor
complex [39]( Table 3).
4. Chronic Inﬂammation Mediated by TLR4 in
Cancer Development andProgression
Numerous links exist between inﬂammation and tumor
development [18]. At the same time inﬂammatory cytokines
Table 3: Human tumors expressing TLR4.
Tumor type References
Adrenocortical cancer [40]
Breast cancer [41]
Bladder cancer [22]
Colon cancer [24, 25, 39]
Gastric cancer [42]
Laryngeal cancer [26]
Lung cancer [43]
Melanoma [27, 28]
Neuroblastoma [29]
Ovarian cancer [9, 30, 31]
Prostate cancer [44]
are indispensable for immune cell activation and antitumor
function. Therefore, there is an apparent contradiction when
we consider the role of inﬂammation in cancer. It is plausible
that part of the answer to this puzzle lies not in the
inﬂammatory stimulation per se but in its timing, duration,
and intensity.
Chronic inﬂammation is often associated with cancer
andcanbetheresultofdiﬀerentcauses,suchasautoimmune
disease or microbial infection.
An example of microbial infection that can predispose
an individual to cancer development is Helicobacter pylori
infection. Infection with H. pylori is a known risk factor in
gastric cancer and has been classiﬁed as a human carcinogen
by the International Agency for Research on Cancer [45].
H. pylori infection is chronic and persistent, because H.
pylori has the ability to evade immune system recognition.
It has unusual endotoxin that exhibits very low endotoxic
activity compared to the more common hexa-acylated
form of endotoxin, usually found in enterobacteria (e.g.,
Escherichia coli)[ 46]. In spite of the inability to stimulate
TLR4 on its own, H. pylori actively promotes inﬂammation
by upregulating TLR4 expression via TLR2 and MEK1/2-
ERK1/2 pathway giving way to TLR4 activation by endotoxin
from other bacteria that pass through the gastrointestinal
tract [47, 48]. TLR4 expression was indeed observed on
gastriccarcinoma tumorcellsas wellas ongastric epithelium
with intestinal metaplasia and dysplasia [42].
Persistent inﬂammation is also a characteristic of colitis-
associated neoplasms. Patients with ulcerative colitis have a4 Clinical and Developmental Immunology
ﬁve to eight times higher risk of developing colorectal cancer
than the rest of the population [49, 50]. TLR4 expression is
upregulated in colitis-associated cancer lesions from patients
with ulcerative colitis but not in the surrounding tissue
[51]. TLR4 seems to promote the development of colitis-
associated colorectal tumors, and mice deﬁcient in TLR4
are markedly protected against the development of neoplasia
[52]. The reason behind this phenomenon could lie in the
TLR4-Cox2-PGE2 signaling axis. Cyclooxygenase-2 (Cox-2)
is aberrantly expressed in the majority of colorectal tumors
and is (along with its enzymatic product prostaglandin E2)
involved in the development of colorectal cancer [53]. It was
recently shown that oral administration of high dosages of
PGE2 can by-pass the protective eﬀect exhibited by TLR4-
deﬁcient mice, which implicates PGE2 as an important TLR4
downstream molecule in colorectal cancer development as
well as a potential target for more eﬀective prevention of
colitis-associated colorectal cancer [54].
TLR4 also has the potential to become a disease progres-
sion marker in patients with colon cancer or premalignant
lesions [55] as well as a biomarker of the aggressive tumor
phenotype in laryngeal carcinoma and breast cancer [41,
56]. Its high expression correlates with poor prognosis
in colorectal cancer patients [57] and in murine models
[58]. Furthermore, TLR4 is associated with liver metas-
tasis; researchers showed an increase in TLR4 expression
in steatotic murine livers following diet-induced obesity.
In a metastatic model of colorectal cancer animals with
steatotic livers had increased metastatic tumor mass within
the liver compared to lean controls. Silencing of TLR4 on
tumors lowered the tumor burden, indicating that tumor
cell TLR4 signaling promotes metastatic growth [58]. On
the contrary other studies concerning colorectal carcinoma
showed correlation between reduced TLR4 expression and
increased metastatic potential of the tumor [39].
TLR4 is associated with metastasis also in other types of
cancer, such as melanoma, where TLR4 activation induces
cell migration [28], and prostate cancer. It was shown that
highly metastatic human prostate cancer cell lines, such as
PC3 or DU145, express higher levels of TLR4 compared to
poorly metastatic cell lines. Moreover, downregulation of
TLR4 expression by siRNA can inhibit prostate cancer cell
invasion in vitro and can improve survival of tumor-bearing
animals [59]. Similar results were shown in human breast
cancer cell line, where downregulation of TLR4 signiﬁcantly
reduced tumor cell proliferation [23].
Conversely, another study [60] reports a decrease in
TLR4 expression in human prostate tissue samples that
correlates with histopathological grade of prostate cancer.
TLR4 expressed in normal and low-grade tumors could
therefore be a contributing factor in chronic inﬂammation
t h a tp r o m o t e sc a r c i n o g e n e s i s[ 61], while decreased TLR4
expressioninmoreaggressivehigh-gradetumorscouldresult
from loss of cell diﬀerentiation that accompanies cancer
progression [60].
A similar phenomenon, though with a diﬀerent underly-
ing cause, can be seen in the case of cervical cancer, where
Yu and coworkers [62] observed downregulation of TLR4
expression during progression of cervical neoplasia. They
have attributed this downregulation to the immunosuppres-
sive eﬀect that persistent human papilloma virusinfection
has on the host immune response [62]. A degree of prudence
is therefore recommended when conclusions are made from
the data currently available, because of major discrepancies
between studies with respect to diﬀerent species, cell culture,
or cancer type studied.
5. Endogenous TLR4 Ligands Responsible for
TLR4 SignalizationinCancer
But what activates TLR4 signaling—is it bacterial endotoxin
or perhaps other ligands? Endotoxin is ubiquitously present
inair,gut,andepithelialsurfaces,andperioperativeexposure
to it is associated with accelerated metastatic tumor growth
[63]. Metastases could be the consequence of activation of
the TLR4 signaling pathway that results in reduced apoptosis
and increased proliferation of metastatic tumor cells. Killeen
and coworkers [64] recently studied the role of endotoxin
and TLR4 in invasion of extracellular matrix (ECM) and
have shown that endotoxin promotes tumor cell ECM
adhesion and invasion through activation of the urokinase
plasminogen activator system (a serine protease that turns
plasminogen into enzymically active plasmin responsible for
blood clot degradation).
It is undisputed that the presence or absence of TLR4
expression on tumor (as well as nontumor) cells can
inﬂuence diﬀerent stages of carcinogenesis. Although many
reports show clear correlation between chronic microbial
infection and cancer initiation (e.g., H. pylori infection),
others fail to provide evidence of the presence of endotoxin
orotherTLR4ligandsatcancerinitiationsites.Animportant
role is therefore attributed to diﬀerent molecules of host
origin that have lately arisen as potential endogenous ligands
of TLR4. These proposed endogenous molecules include dif-
ferent components of the extracellular matrix, intracellular
proteins, or modiﬁed lipids or lipoproteins (summarized
in Table 4). Interestingly, many of them are proposed to
activate both TLR4 and TLR2 without having any substantial
structural similarity to their natural ligands (endotoxin or
lipopeptides, resp.).
Because many (if not most) of the studies describing
putative endogenous TLR4 ligands (Table 4) used recom-
binant proteins and/or commercial reagents with unde-
termined levels of residual endotoxin, it is reasonable to
raise concerns about the purity of the putative ligands
used in experiments. The most common methods used to
exclude potential endotoxin contamination are the limulus
amebocyte lysate (LAL) test and endotoxin neutralization
with polymyxin B (PMB). Some researchers demonstrate
that their proposed TLR ligands lose their activating capacity
after exposure to elevated temperatures. But as described in
an excellent review by Erridge [104], these methods have
a major shortfall when used in studies describing novel
endogenous TLR4 ligands. LAL test, for example, is unable
to detect endotoxin in the presence of endotoxin-binding
molecules. Furthermore, molecules that bind endotoxin
can also prevent its inactivation by PMB. As for the heatClinical and Developmental Immunology 5
Table 4
Proposed endogenous TLR4
ligand Reference
Advanced glycation end
product low-density
lipoprotein
AGE-LDL [65]
Angiotensin II [66, 67]
Beta defensin [68, 69]
Biglycan [70, 71]
Calprotectin [72]
Ceramide [73]
Fibrinogen [74, 75]
Fibronectin extra domain A F-EDA [76, 77]
High-mobility group box 1 HMGB1 [78–81]
Heat shock protein HSP [82–85]
Heparan sulfate [86]
Hyaluronan [87–92]
Minimally modiﬁed
(oxidized) low-density
lipoprotein
mmLDL [93–95]
Myeloid-related protein-8/14 MRP-8/14 [96]
Oxidized
Palmitoyl-arachidonoyl-
phosphatidylcholine
OxPAPC [97, 98]
Pancreatic adenocarcinoma
upregulated factor PAUF [99]
Serum amyloid A [100]
Saturated fatty acid SFA [101]
Surfactant protein A [102]
Tenascin-C [103]
sensitivity, the biological activity of endotoxin can be greatly
r e d u c e db ye l e v a t e dt e m p e r a t u r e s .
High-mobility group box-1 protein (HMGB1) is a
putative TLR4 ligand implicated in cancer. HMGB1 is a
nuclear DNA-binding protein that is actively secreted from
cells following cytokine stimulation or passively released
during cell death. It signals through the receptor for
advancedglycationendproducts(RAGE)[105]andhasbeen
implicatedinavarietyofimmuneprocessesandpathological
conditions including cancer [106, 107]. In the past few years
many studies reported signalization of HMGB1 through
TLR4 and declared HMGB1 an endogenous ligand of TLR4
[79, 80, 107]. HMGB1 is connected in several ways to
tumor progression and metastasis [105]. On the other
hand, HMGB1 released from irradiated or doxorubicin-
/oxaliplatin- treated cells can improve immunogenicity of
dying tumor cells and therefore help improve tumor antigen
presentation [107]. A substantial number of studies show
that HMGB1 however binds agonists of TLR, predominantly
anionic molecules such as LPS [108], poly(IC), and CpG
ODN that activate TLR4, TLR3, and TLR9; therefore, it
may act as a chaperone [109, 110], similar to CD14, which
stimulates activation of TLR4, TLR3, TLR7, and TLR9 by
their agonists [111–113]. Additionally HMGB1 produced in
mammalian cell cultures and therefore devoid of bacterial
contaminantsorendogenousdangersignalsdoesnotactivate
TLR4 (unpublished observation). It should therefore be
reconsidered whether these TLR4 ligands are not in fact
just endotoxin-binding or endotoxin-sensitizing molecules
without the intrinsic capability of binding and activating
TLR4 on their own [104].
It is diﬃcult to comprehend the multitude of the pro-
posed TLR4 agonists that bear no structural similarity to
the lipid A moiety of the LPS that is the only TLR4
agonist that has been prepared by chemical synthesis and
whose molecular mechanism of activation is known [15,
16]. With respect to the plausible molecular mechanism
of the direct activation of TLR4/MD-2 signaling complex
oxidatively modiﬁed endogenous lipids seem to be the
most likely ubiquitous endogenous agonists (Manˇ cek-Keber,
manuscript in preparation).
6.BreakingtheImmuneT oleranceofT umorsby
TLR4 Stimulation
Toll-like receptor activation is the trigger that sets the
immune system into action. The application of TLR ligands
in cancer therapy is therefore an attractive possibility that
has been intensively studied in the past years in the context
of cancer treatment or prevention (as anti-tumor vaccine
adjuvants). Macrophages stimulated by endotoxin respond
by secretion of chemokines and proinﬂammatory cytokines,
including TNFα and interleukin-1β, which coordinate local
and systemic inﬂammatory responses [17]. Dendritic cells,
stimulatedbyendotoxin,secreteIL-12,whichisimportantin
anti-tumorimmunity[114].Furthermore,TLR4stimulation
induces DC maturation and antigen presentation, which
has important eﬀect on adaptive immune responses [4].
TLR stimulation inﬂuences antigen processing and presen-
tation [115]b ya ﬀecting the expression of costimulatory
molecules on the surface of antigen-presenting cells as well
as by controlling antigen uptake [116, 117]a n dp h a g o s o m e
maturation [118]. In addition to presenting antigens to lym-
phocytes, mature DCs are also capable of activating cancer-
speciﬁc natural killer and NKT cells [119]. Inversely, TLR-
stimulated NK cells facilitate in immature DC activation and
maturation[120]andhelpintensifyDC-mediatedantitumor
immune responses [121].
Tumors consist in large part not only of tumor but
also of immune cells. It is therefore reasonable to assume
that direct application of TLR ligands will aﬀect both types
of cells. TLR stimulation will possibly have even greater
eﬀect on the immune cell population, since not all tumor
cells express TLR or the expression varies depending on the
developmental stage of the tumor.
This is evident form an example of Bacillus Calmette-
Guerin (BCG), an attenuated strain of Mycobacterium bovis
that is used in the current treatment of nonmuscle invasive6 Clinical and Developmental Immunology
bladder cancer [122]. BCG promotes dendritic cell matura-
tion, and this eﬀect is TLR4 (as well as TLR2) dependent
[123]. Furthermore, BCG can induce expression of TNF-
related apoptosis-inducing ligand (TRAIL) on tumor inﬁl-
trating dendritic cells, therefore rendering them cytotoxic
against tumor cells [124].
Another example of an immune activator of microbial
origin that promotes dendritic cell maturation is the strep-
tococcal agent OK-432. OK-432 is a preparation of a killed
low-virulence strain of Streptococcus pyogenes that has been
successfully used for over 30 years as an immunotherapeutic
agent in diﬀerent malignancies [125]. Its mechanism of
action apparently involves TLR4 activation, since OKA-
432 does not inhibit tumor growth on TLR4 knockouts as
it does on wild-type mice. Moreover, patients with head
and neck cancer responded to OK-432 treatment combined
with ﬂuoropyrimidine chemotherapy and radiation signif-
icantly better if they expressed TLR4 and MD-2 mRNA
(compared to patients without TLR4 or MD-2 expression)
[126, 127].
Stimulation of TLR4 on tumor cells can give contradict-
ing results in terms of cancer progression versus treatment.
The outcome seems to be species, tissue, and tumor type
dependent. While TLR4 stimulation is on one hand associ-
ated with cancer progression (discussed above), it can also
lead to anti-tumor immune response. B16 melanoma cells,
for instance, that were stimulated with endotoxin in vitro
exhibit reduced capability of inducing tumor growth in vivo.
This response was totally independent of TLR4 expression
by nontumor cells. In vitro stimulated tumor cells seem to
diﬀerentially inﬂuence the phenotype of tumor inﬁltrating
lymphocytes (TILs) so that TILs produced elevated levels
of IFN-gamma and reduced levels of IL-10, thus favorably
aﬀecting the intratumoral cytokine balance [10].
7. Radio- and Chemotherapy
CanEnhanceAntitumorImmunityby
ProvidingTLRLigands
Combining immunotherapy and radiation is a new, com-
pelling approach to cancer therapy. Though radiation is
considered mostly immunosuppressive, it is noted also for
its immunostimulatory eﬀects. Patients therefore beneﬁt
from radiation therapy not only because it directly damages
tumor cells but also because suppressor T-cell populations
appeartobemoreradiosensitivethaneﬀectorTlymphocytes
[128]. Radiation can beneﬁt anti-tumor immunity also by
increasing expression of inﬂammatory cytokines by den-
dritic cells, therefore aﬀecting their phenotype and function
[129]. Dendritic cells are critical for anti-tumor immunity
because of their ability to cross-present tumor antigens to
speciﬁc CD8+ T lymphocytes. For eﬃcient antigen cross-
presentation, DCs need to receive appropriate stimulation
through innate immune receptors. Since immature DCs
can induce anti-tumor immunity when administered into
irradiated tumors without the addition of TLR ligands
[130], radiation was hypothesized to provide the necessary
stimulus.
Apetoh et al. [107] recently proposed that HMGB1,
which is released from irradiated tumor cells, acts as an
endogenous TLR4 ligand. They demonstrated that TLR4 is
essential for eﬃcient tumor antigen cross-presentation fol-
lowing radio- or chemotherapy and proposed that HMGB1
binds and activates TLR4 on DCs. HMGB1 could therefore
activate DCs and prevent the accelerated degradation of
the phagocytosed tumor antigens within DCs promoting
eﬃcient tumor antigen processing and cross-presentation
[107]( Figure 2).
The crucial role of TLR4 in immunostimulatory eﬀects
of radiation was also emphasized in a study by Paulos et
al. [131], where they demonstrated elevated serum levels of
endotoxin in mice following whole body irradiation. They
showed that microbial endotoxin that translocated from the
radiation-injured gut was responsible for enhanced anti-
tumor eﬀect of radiation. Moreover, radiation had dimin-
ished eﬀect on tumors following removal of translocated
endotoxin or in mice that were defective in the TLR4
signaling pathway [131]. These ﬁndings could be especially
relevant for the treatment of gastrointestinal malignancies.
8. Cancer Vaccines Utilizing TLR4 Activation
Tumor cell lysates or puriﬁed tumor-associated antigens
for vaccines have been used for therapeutic or prophylactic
cancer vaccine. Although cell lysates contain endogenous
danger signals that act as adjuvants, strong response against
tumor-associated antigens requires additional stimulation of
adaptive immune response by Toll-like receptor agonists.
Agonists of TLR9 (CpG ODN), TLR3 (poly(IC), and TLR4
(endotoxin analogues) have been used to increase the innate
immune response and activate antigen-presenting cells of
the host. TLR4 is particularly important for development
of a strong adaptive immune response by stimulation of the
antibody class switching, aﬃnity maturation, and formation
of memory cells [132]. TLR4 is expressed on follicular
dendritic cells that are essential for the aﬃnity maturation
in germinal centers [133, 134]. Systemic eﬀect and toxicity
of LPS preclude its application for cancer immunotherapy
that started by the early attempts by William Coley. MPLA
is a monophosphorylated lipid A derivative that has several
orders of magnitude lower toxicity than lipid A and was
reported to preferentially activate TRIF-dependent pathway
[135]. MPLA has been registered as a vaccine adjuvant and
used in clinical vaccines, such as Cervarix against human
papilomavirus. MPLA is the only TLR4 agonist that has
been clinically tested as an adjuvant for cancer vaccines.
Results in clinical trials have been modest but seem to be
much better if the vaccines are used in early stages of the
disease, such as, for example, therapy of non-small-cell lung
carcinoma (NSCLC) using MAGE-3 antigen combined with
MPLA-based adjuvant AS02B rather than in late stages,
when the immune system of patients is already severely
compromised (reviewed in [136]). Additional alternative
therapeutic approaches are based on combination of TLR4
agonist as a vaccine adjuvant with tumor-associated antigens
in combination with radio- or chemotherapy or autologous
dendritic cell therapy.Clinical and Developmental Immunology 7
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Figure 2: TLR4 signaling in cancer—a struggle of antitumor immunity against cancer proliferation and immune evasion. TLR4 signaling
on immune cells can enhance anti-tumor immunity by diﬀerent mechanisms, including IL-12 or IFNγ upregulation and promotion of DC
maturation and function (left side of the ﬁgure, depicted in green). On the other hand, TLR4 signaling on tumor cells can increase their
tumorigenic potential (right side of the ﬁgure, depicted in red).
9. Conclusions
TLR signaling triggers immune cell activation and matura-
tion and is indispensable for the eﬃcient immune response
against the pathogenic microorganisms as well as against
malignant cells. An eﬀective immune system is most impor-
tantintheearlystagesofcarcinogenesiswhencancerouscells
are few and are not limited to less immunogenic cell clones.
Ifimmunosurveillance againstmalignantlytransformedcells
is unsuccessful in the early stage, tumors quickly outgrow
the immune cell cytotoxic capabilities. TLR4 expression by
tumorcellscanbeacontributingfactorthatpromotestumor
cell proliferation, survival, or immunosuppression.
Therapeutic interventions at the level of TLR4 stim-
ulation is a double-edged sword since diﬀerent studies
d e m o n s tra t ep o s i t i v ea sw e lla sn e ga t i v ee ﬀects of TLR4 stim-
ulation on cancer development or treatment. Harnessing the
beneﬁcial eﬀects of TLR4 stimulation while eliminating the
negative ones remains the challenge for cancer researchers.
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